Lilly Oncology has launched a novel value assessment tool that aggregates 40 years of oncology data to measure progress and identify unmet needs in cancer treatments.
Eli Lilly & Co. didn't ask Dan Goldstein, an oncologist at the Winship Cancer Institute at Emory University, to price their drugs, but he volunteered his services anyway.
The American Cancer Society published a breast cancer screening guideline that steers toward the middle course in deciding when mammography screening should start and how often it should be performed.
The Cancer Letter invited Richard Wender, chief cancer control officer of the American Cancer Society, to describe the rationale for the society’s new guideline for breast cancer screening.
The National Academy of Medicine elected 80 members during its annual meeting, including at least 17 whose work focuses on cancer treatment and research.
I have watched the rhetoric and heated debate about screening at age 40, now 45, and 50 for 25 years and am miffed that the discussion consistently ignores the obvious things we can do to save lives.
Vice President Joe Biden, in a Rose Garden address announcing his decision to not run for president, called for a national commitment to end cancer—expressing that, were he to run and be elected, it would be a goal of his presidency.
The National Comprehensive Cancer Network unveiled a new initiative—NCCN Evidence Blocks—in the new versions of the NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia and Multiple Myeloma.
The 340B Drug Discount Program—designed to help hospitals that serve needy patients—is on the brink of a major revamp.
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
